| __timestamp | Amicus Therapeutics, Inc. | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 14097000000 |
| Thursday, January 1, 2015 | 47269000 | 14809000000 |
| Friday, January 1, 2016 | 71151000 | 14837000000 |
| Sunday, January 1, 2017 | 88671000 | 14784000000 |
| Monday, January 1, 2018 | 127200000 | 14455000000 |
| Tuesday, January 1, 2019 | 169861000 | 14350000000 |
| Wednesday, January 1, 2020 | 156407000 | 11615000000 |
| Friday, January 1, 2021 | 192710000 | 12703000000 |
| Saturday, January 1, 2022 | 213041000 | 13677000000 |
| Sunday, January 1, 2023 | 275270000 | 14771000000 |
| Monday, January 1, 2024 | 14730000000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. Over the past decade, Pfizer Inc. and Amicus Therapeutics, Inc. have showcased contrasting strategies in managing Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. This consistency reflects Pfizer's robust operational framework. In contrast, Amicus Therapeutics has seen a dramatic increase in SG&A expenses, growing by over 1,200% from 2014 to 2023. This surge indicates Amicus's aggressive expansion and investment in administrative capabilities. While Pfizer's expenses dwarf those of Amicus, the latter's rapid growth trajectory highlights its dynamic approach in a competitive market. This analysis underscores the diverse strategies companies employ to balance growth and efficiency in the pharmaceutical sector.
Pfizer Inc. and Viatris Inc.: SG&A Spending Patterns Compared
Pfizer Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Walgreens Boots Alliance, Inc.
Comparing SG&A Expenses: Pfizer Inc. vs Cytokinetics, Incorporated Trends and Insights
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Bio-Techne Corporation or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Amicus Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Amicus Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of MorphoSys AG and Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.